- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT04044768
Speerpunt 1 studie bij proefpersonen met gevorderd synoviaal sarcoom of myxoïde/rondcelliposarcoom
Een fase 2 open-label klinisch onderzoek met één arm van ADP-A2M4 SPEAR™ T-cellen bij proefpersonen met geavanceerd synoviaal sarcoom of myxoïde/rondcelliposarcoom
This is a study to investigate the efficacy and safety of ADP-A2M4 in HLA-A*02 eligible and MAGE-A4 positive subjects with metastatic or inoperable (advanced) Synovial Sarcoma (Cohort 1, 2 and 3 ) or MRCLS (Cohort 1) .
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- Princess Margaret Cancer Centre
-
-
-
-
-
Lyon, Frankrijk
- Centre Leon Berard
-
Pessac, Frankrijk, 33604
- Hospital Haut Leveque, CHU Bordeaux
-
Villejuif, Frankrijk, 94805
- Gustave Roussy Cancer Center
-
-
-
-
-
Madrid, Spanje, 28040
- Start Madrid-FJD, Fundación Jimѐnez Díaz
-
Seville, Spanje, 41013
- Hospital Universitario Virgen del Rocio
-
-
Catalonia
-
Barcelona, Catalonia, Spanje, 119-129
- Hospital Universitari Vall D'Hebron
-
-
-
-
-
London, Verenigd Koninkrijk, NW1 2PG
- UCLH Cancer Clinical Trials Unit
-
Manchester, Verenigd Koninkrijk, M20 4BX
- The Christie NHS Foundation Trust
-
-
-
-
California
-
Duarte, California, Verenigde Staten, 91010
- City of Hope
-
Palo Alto, California, Verenigde Staten, 94305
- Stanford Cancer Center
-
-
Colorado
-
Aurora, Colorado, Verenigde Staten, 80045
- University of Colorado
-
-
Florida
-
Jacksonville, Florida, Verenigde Staten, 33612
- Mayo Clinic Jacksonville
-
Tampa, Florida, Verenigde Staten, 33612
- Moffitt Cancer Center
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60611
- Northwestern University Robert H. Lurie Comprehensive Cancer Center
-
-
Maryland
-
Bethesda, Maryland, Verenigde Staten, 20892
- National Cancer Institute
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, Verenigde Staten, 02215
- Dana Farber Cancer Institute
-
-
Michigan
-
Ann Arbor, Michigan, Verenigde Staten, 48109
- University of Michigan
-
-
Missouri
-
St Louis, Missouri, Verenigde Staten, 63110
- Washington University School of Medicine
-
-
New York
-
New York, New York, Verenigde Staten, 10065
- Memorial Sloan-Kettering Cancer Center
-
-
Ohio
-
Columbus, Ohio, Verenigde Staten, 43210
- Ohio State University
-
-
Tennessee
-
Nashville, Tennessee, Verenigde Staten, 37212
- Vanderbilt
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77030
- MD Anderson Cancer Center
-
-
Washington
-
Seattle, Washington, Verenigde Staten, 98109
- Fred Hutch
-
-
Wisconsin
-
Milwaukee, Wisconsin, Verenigde Staten, 53226
- Medical College of WI Froedtert Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Key Inclusion Criteria
- Age ≥16 (10 years at selected sites) and <=75 years
- Diagnosis of advanced synovial sarcoma (Cohort 1, Cohort 2 and Cohort 3) or myxoid liposarcoma / myxoid round cell liposarcoma (Cohort 1 only) confirmed by cytogenetics.
- Previously received either an anthracycline or ifosfamide containing regimen.
- Measurable disease according to RECIST v1.1 prior to lymphodepletion
- HLA-A*02:01, HLA-A*02:02, HLA-A*02:03 or HLA-A*02:06 positive
- Tumor shows MAGE-A4 expression confirmed by central laboratory. North America Only (United States and Canada): Tumor (either an archival specimen or a fresh biopsy) shows MAGE-A4 expression of ≥2+ staining in ≥30% of the cells by immunohistochemistry.
- ECOG Performance Status of 0 or1. For subjects aged ≥10 to ≥16 years old:
Lansky Score ≥60%.
• Left ventricular ejection fraction (LVEF) ≥50%.
Note: other protocol defined Inclusion criteria may apply
Key Exclusion Criteria:
- HLA-A*02:05 in either allele
- Received or plans to receive the following therapy/treatment prior to leukapheresis or lymphodepleting chemotherapy: Cytotoxic chemotherapy, Tyrosine kinase inhibitor (TKI) (e.g. pazopanib), Immune therapy (including monoclonal antibody therapy, checkpoint inhibitors,), Anti-cancer Vaccine, Gene therapy using an integrating vector (subjects who have received a gene therapy using a lentiviral vector may be eligible for the study), Corticosteroids or any other immunosuppressive therapy, Investigational treatment or interventional clinical trial, Allogeneic hematopoietic stem cell transplant, Radiotherapy to the target lesions, Major surgery
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to fludarabine, cyclophosphamide or other agents used in the study.
- History of autoimmune or immune mediated disease
- Symptomatic CNS metastases including leptomeningeal disease.
- Other prior malignancy that is not considered by the Investigator to be in complete remission
- Clinically significant cardiovascular disease
- Uncontrolled intercurrent illness
- Active infection with human immunodeficiency virus, hepatitis B virus, hepatitis C virus, or human T cell leukemia virus
- Pregnant or breastfeeding
Note: other protocol defined Exclusion criteria may apply.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Autologe genetisch gemodificeerde afamitresgene autoleucel (voorheen ADP-A2M4) SPEAR™ T-cellen
|
Single infusion of autologous genetically modified afamitresgene autoleucel (previously ADP-A2M4) Dose: 1.0 x109 to 10x109 transduced by a single intravenous infusion |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Overall Response Rate (ORR) (Cohort 1)
Tijdsspanne: From T-cell infusion until disease progression/recurrence as of data cut off (up to 2 years). Response was assessed at Week 4, Week 8, Week 12, Week 16, and Week 24, and every 2 months +/- 28 days until confirmed disease progression.
|
Percentage of participants with confirmed tumor response (complete [CR] or partial [PR] response) to treatment as assessed using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Independent Radiologist review (Cohort 1) |
From T-cell infusion until disease progression/recurrence as of data cut off (up to 2 years). Response was assessed at Week 4, Week 8, Week 12, Week 16, and Week 24, and every 2 months +/- 28 days until confirmed disease progression.
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Adverse Events (AE) Including Serious Adverse Events (SAE), SAE, and Adverse Events of Special Interest (AESI) (Cohort 1)
Tijdsspanne: AEs, SAEs, and AESIs were collected at each visit from the start of lymphodepletion of the first subject until the last subject discontinued the interventional phase in cohort 1 as of the safety cut off (up to 3.2 years).
|
An AE was defined as any untoward medical occurrence in a subject or clinical study participant temporally associated with the use of the study intervention, whether or not considered related to the study intervention. Therefore, an AE could have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. The number of participants with AEs (including SAE), SAE and AESI including cytokine release syndrome, neurotoxicity, ICANS, prolonged cytopenia are presented. |
AEs, SAEs, and AESIs were collected at each visit from the start of lymphodepletion of the first subject until the last subject discontinued the interventional phase in cohort 1 as of the safety cut off (up to 3.2 years).
|
|
The Number of Participants With Replication Competent Lentivirus (RCL)
Tijdsspanne: From T-cell infusion to months 3, 6, and 12 post-infusion, then annually post-infusion (up to 2.8 years as of the data cut off).
|
The presence of RCL was assessed by qPCR targeting a segment of the vesicular stomatitis virus glycoprotein (VSV G) coding sequence. |
From T-cell infusion to months 3, 6, and 12 post-infusion, then annually post-infusion (up to 2.8 years as of the data cut off).
|
|
Insertional Oncogenesis (IO)
Tijdsspanne: From 10 months post T-cell infusion up to 20 months post T-cell infusion (as of the data cut off)
|
Deoxyribonucleic acid (DNA) from participants peripheral blood mononuclear cell (PBMC) samples was subjected to lentiviral vector integration site analysis by next-generation sequencing, thus evaluating both the clonality status of the transduced cell population and the genomic localization of individual integration sites. The count of participants with integration sites representing more than 5% of all unique sites is presented. |
From 10 months post T-cell infusion up to 20 months post T-cell infusion (as of the data cut off)
|
|
Best Overall Response (BOR) (Cohort 1)
Tijdsspanne: From T-cell infusion until disease progression/recurrence as of data cut off (up to 2.6 years). Response was assessed at Week 4, Week 8, Week 12, Week 16, and Week 24, and every 2 months +/- 28 days until confirmed disease progression.
|
BOR is the best response recorded from the start of T-cell infusion until disease progression/recurrence as assessed by Independent Radiologist review. Response categories are confirmed CR, confirmed PR, stable disease and confirmed progressive disease (PD). Best overall response is a stable disease, if CR or PR are unconfirmed. |
From T-cell infusion until disease progression/recurrence as of data cut off (up to 2.6 years). Response was assessed at Week 4, Week 8, Week 12, Week 16, and Week 24, and every 2 months +/- 28 days until confirmed disease progression.
|
|
Time to Response (TTR) (Cohort 1)
Tijdsspanne: From T-cell infusion until first documented confirmed CR or confirmed PR. Response was assessed at Week 4, Week 8, Week 12, Week 16, and Week 24, and every 2 months +/- 28 days until confirmed disease progression.
|
TTR was defined as the interval (weeks) from the date of T-cell infusion to the earliest date of the first documented confirmed CR or confirmed PR as assessed by Independent Radiologist review. TTR (in weeks) = [date of initial confirmed CR or PR - date of T-cell infusion + 1]/7. |
From T-cell infusion until first documented confirmed CR or confirmed PR. Response was assessed at Week 4, Week 8, Week 12, Week 16, and Week 24, and every 2 months +/- 28 days until confirmed disease progression.
|
|
Duration of Response (DoR) (Cohort 1)
Tijdsspanne: From initial confirmed response (CR or PR) until PD (or censored date) as of data cut off.
|
DoR (in months) is defined as ((date of PD (or censoring) - date of initial confirmed CR/PR + 1)/365.25)*12 as assessed by Independent Radiologist review. Outcome Measure not yet reached as participants are ongoing in study |
From initial confirmed response (CR or PR) until PD (or censored date) as of data cut off.
|
|
Progression Free Survival (PFS) (Cohort 1)
Tijdsspanne: From T-cell infusion until first documented PD or death due to any cause (or censored date), whichever occurs first, as of data cut off (up to 2.6 years). Response was assessed at Week 4, 8,12,16, 24, and every 2 months until confirmed PD
|
PFS is defined as the time from T-cell infusion to the date of the first documentation of PD or death due to any cause, whichever occurs first, as assessed by Independent Radiologist review. PFS (in weeks) was calculated as (date of PD/death [or censored date] - first T-cell infusion date + 1)/7. |
From T-cell infusion until first documented PD or death due to any cause (or censored date), whichever occurs first, as of data cut off (up to 2.6 years). Response was assessed at Week 4, 8,12,16, 24, and every 2 months until confirmed PD
|
|
Overall Survival (OS) (Cohort 1)
Tijdsspanne: From T-cell infusion to death due to any reason (or censored date) as of data cut off (up to 2.6 years).
|
OS is defined as the time from the date of T-cell infusion to the date of death (due to any reason) or censored date. OS in months was calculated as ((death date - first T-cell infusion date + 1)/365.25)*12. Outcome Measure not yet reached as participants are ongoing in study |
From T-cell infusion to death due to any reason (or censored date) as of data cut off (up to 2.6 years).
|
|
Peak Persistence (Cohort 1)
Tijdsspanne: From T-cell infusion to 3.2 years (as of data cut off).
|
Peak persistence of afamitresgene autoleucel cells was reported as vector copy numbers per microgram of genomic DNA from peripheral blood mononuclear cell (PBMC). |
From T-cell infusion to 3.2 years (as of data cut off).
|
|
Time Taken to Achieve Peak Expansion of Genetically Engineered T-cells in PBMCs
Tijdsspanne: 2.5 years
|
Time taken to achieve peak expansion of genetically engineered T-cells in PBMCs by flow cytometry |
2.5 years
|
|
Quantitation of Genetically Engineered T-cells in PBMCs
Tijdsspanne: 2.5 years
|
Quantitation of genetically engineered T-cells in PBMCs by flow cytometry |
2.5 years
|
|
Time Taken to Achieve Peak Expansion of Genetically Engineered T-cells in PBMCs
Tijdsspanne: 2.5 years
|
Time taken to achieve peak expansion of genetically engineered T-cells in PBMCs by qPCR |
2.5 years
|
|
In Vitro Diagnostic (IVD) Assay for Screening
Tijdsspanne: 2.5 years
|
Development and validation of the MAGE-A4 antigen expression companion diagnostic assay |
2.5 years
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Dejka Araujo, MD, MD Anderson Cancer Center; Houston TX 77030
Publicaties en nuttige links
Algemene publicaties
- Sanderson JP, Crowley DJ, Wiedermann GE, Quinn LL, Crossland KL, Tunbridge HM, Cornforth TV, Barnes CS, Ahmed T, Howe K, Saini M, Abbott RJ, Anderson VE, Tavano B, Maroto M, Gerry AB. Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapy. Oncoimmunology. 2019 Nov 24;9(1):1682381. doi: 10.1080/2162402X.2019.1682381. eCollection 2020.
- D'Angelo SP, Araujo DM, Abdul Razak AR, Agulnik M, Attia S, Blay JY, Carrasco Garcia I, Charlson JA, Choy E, Demetri GD, Druta M, Forcade E, Ganjoo KN, Glod J, Keedy VL, Le Cesne A, Liebner DA, Moreno V, Pollack SM, Schuetze SM, Schwartz GK, Strauss SJ, Tap WD, Thistlethwaite F, Valverde Morales CM, Wagner MJ, Wilky BA, McAlpine C, Hudson L, Navenot JM, Wang T, Bai J, Rafail S, Wang R, Sun A, Fernandes L, Van Winkle E, Elefant E, Lunt C, Norry E, Williams D, Biswas S, Van Tine BA. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. Lancet. 2024 Apr 13;403(10435):1460-1471. doi: 10.1016/S0140-6736(24)00319-2. Epub 2024 Mar 27.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- ADP 0044-002
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .